Trial record 1 of 1 for:
FINER ipatasertib | Breast Cancer
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04650581 |
|
Recruitment Status :
Active, not recruiting
First Posted : December 2, 2020
Last Update Posted : May 9, 2024
|
Sponsor:
Canadian Cancer Trials Group
Collaborator:
Hoffmann-La Roche
Information provided by (Responsible Party):
Canadian Cancer Trials Group
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | June 30, 2024 |
| Estimated Study Completion Date : | December 31, 2026 |